Unknown

Dataset Information

0

Patiromer.

ABSTRACT: Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The April 2016 monograph topics are von Willebrand factor (recombinant), daratumumab, elotuzumab, uridine triacetate, and ixazomib. The MUE is on lesinurad.

SUBMITTER: Cada DJ 

PROVIDER: S-EPMC4896336 | biostudies-other | 2016 Apr

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Patiromer.

Cada Dennis J DJ   Dang Jessica J   Baker Danial E DE  

Hospital pharmacy 20160401 4

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription,  ...[more]

Similar Datasets

Unknown LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1.
2017-03-14 | LDS-1250 | LINCS
Unknown MGH (CMT) Growth Inhibition Assay Protocol (9 compound doses: 16 uM to 0.0625 uM) -- DNA Staining
2014-05-30 | EDS-1011 | LINCS
Unknown Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values.
2017-03-14 | LDS-1261 | LINCS
Unknown MGH (CMT) Growth Inhibition Assay Protocol (9 compound doses: 0.512 uM to 0.002 uM) -- DNA Staining
2014-05-30 | EDS-1007 | LINCS
Unknown MGH (CMT) Growth Inhibition Assay Protocol (9 compound doses: 10.24 uM to 0.04 uM) -- DNA Staining
2014-05-30 | EDS-1010 | LINCS
Unknown MEMA PC3 Staining Set 1
2016-03-09 | LDS-1311 | LINCS
Unknown MEMA HMEC240L Staining Set 1
2016-11-10 | LDS-1435 | LINCS
Unknown MEMA HMEC122L Staining Set 1
2016-11-10 | LDS-1427 | LINCS
Unknown Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen.
2017-07-20 | LDS-1364 | LINCS
Unknown Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 1 of 4)
2017-01-20 | LDS-1368 | LINCS